{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:53:14Z","timestamp":1773658394799,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hyperhomocysteinemia (HHcy) and hyperglycemia cause diabetic cardiomyopathy by inducing oxidative stress and attenuating peroxisome proliferator- activated receptor (PPAR) gamma. However, their synergistic contribution is not clear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Diabetic Akita (Ins2+\/-) and hyperhomocysteinemic cystathionine beta synthase mutant (CBS+\/-) were used for M-mode echocardiography at the age of four and twenty four weeks. The cardiac rings from WT, Akita and hybrid (Ins2+\/-\/CBS+\/-) of Akita and CBS+\/- were treated with different doses of acetylcholine (an endothelial dependent vasodilator). High performance liquid chromatography (HPLC) was performed for determining plasma homocysteine (Hcy) level in the above groups. Akita was treated with ciglitazone (CZ) - a PPAR gamma agonist and tempol-an anti-oxidant, separately and their effects on cardiac remodeling were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At twenty four week, Akita mice were hyperglycemic and HHcy. They have increased end diastolic diameter (EDD). In their heart PPAR gamma, tissue inhibitor of metalloproteinase-4 (TIMP-4) and anti-oxidant thioredoxin were attenuated whereas matrix metalloproteinase (MMP)-9, TIMP-3 and NADPH oxidase 4 (NOX4) were induced. Interestingly, they showed synergism between HHcy and hyperglycemia for endothelial-myocyte (E-M) uncoupling. Additionally, treatment with CZ alleviated MMP-9 activity and fibrosis, and improved EDD. On the other hand, treatment with tempol reversed cardiac remodeling in part by restoring the expressions of TIMP-3,-4, thioredoxin and MMP-9.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Endogenous homocysteine exacerbates diabetic cardiomyopathy by attenuating PPAR gamma and inducing E-M uncoupling leading to diastolic dysfunction. PPAR gamma agonist and tempol mitigates oxidative stress and ameliorates diastolic dysfunction in diabetes.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1475-2840-9-49","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T18:14:09Z","timestamp":1284056049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol"],"prefix":"10.1186","volume":"9","author":[{"given":"Paras K","family":"Mishra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neetu","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utpal","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irving G","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh C","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,9]]},"reference":[{"key":"268_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/157488410790410551","volume":"5","author":"M Ciaccio","year":"2010","unstructured":"Ciaccio M, Bellia C: Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol. 2010, 5: 30-36. 10.2174\/157488410790410551.","journal-title":"Curr Clin Pharmacol"},{"key":"268_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.33588\/rn.5004.2009081","volume":"50","author":"J Mendez-Gonzalez","year":"2010","unstructured":"Mendez-Gonzalez J, Rodriguez-Millan E, Julve J, Blanco-Vaca F: [Vitamin treatments that lower homocysteine concentration: can they decrease cerebrovascular disease in primary prevention?]. Rev Neurol. 2010, 50: 235-244.","journal-title":"Rev Neurol"},{"key":"268_CR3","doi-asserted-by":"publisher","first-page":"806538","DOI":"10.1155\/2010\/806538","volume":"2010","author":"U Sen","year":"2010","unstructured":"Sen U, Tyagi SC: Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?. PPAR Res. 2010, 2010: 806538.","journal-title":"PPAR Res"},{"key":"268_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0021-9150(01)00531-7","volume":"159","author":"MC Audelin","year":"2001","unstructured":"Audelin MC, Genest J: Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis. 2001, 159: 497-511. 10.1016\/S0021-9150(01)00531-7.","journal-title":"Atherosclerosis"},{"key":"268_CR5","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1524-6175.2004.03643.x","volume":"6","author":"R Dinavahi","year":"2004","unstructured":"Dinavahi R, Falkner B: Relationship of homocysteine with cardiovascular disease and blood pressure. J Clin Hypertens (Greenwich). 2004, 6: 494-498. 10.1111\/j.1524-6175.2004.03643.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"268_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07315724.2010.10719810","volume":"29","author":"LJ Dominguez","year":"2010","unstructured":"Dominguez LJ, Galioto A, Pineo A, Ferlisi A, Ciaccio M, Putignano E, et al: Age, homocysteine, and oxidative stress: relation to hypertension and type 2 diabetes mellitus. J Am Coll Nutr. 2010, 29: 1-6.","journal-title":"J Am Coll Nutr"},{"key":"268_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/01.ATV.18.1.133","volume":"18","author":"EK Hoogeveen","year":"1998","unstructured":"Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, et al: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998, 18: 133-138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"268_CR8","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1161\/01.CIR.101.13.1506","volume":"101","author":"EK Hoogeveen","year":"2000","unstructured":"Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, et al: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation. 2000, 101: 1506-1511.","journal-title":"Circulation"},{"key":"268_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/bmj.325.7374.1202","volume":"325","author":"DS Wald","year":"2002","unstructured":"Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002, 325: 1202-10.1136\/bmj.325.7374.1202.","journal-title":"BMJ"},{"key":"268_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/diacare.23.1.84","volume":"23","author":"C Pavia","year":"2000","unstructured":"Pavia C, Ferrer I, Valls C, Artuch R, Colome C, Vilaseca MA: Total homocysteine in patients with type 1 diabetes. Diabetes Care. 2000, 23: 84-87. 10.2337\/diacare.23.1.84.","journal-title":"Diabetes Care"},{"key":"268_CR11","doi-asserted-by":"crossref","unstructured":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002, 288: 2015-2022. 10.1001\/jama.288.16.2015.","DOI":"10.1001\/jama.288.16.2015"},{"key":"268_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.amjhyper.2004.11.035","volume":"18","author":"JF Carroll","year":"2005","unstructured":"Carroll JF, Tyagi SC: Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am J Hypertens. 2005, 18: 692-698. 10.1016\/j.amjhyper.2004.11.035.","journal-title":"Am J Hypertens"},{"key":"268_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/FJC.0b013e31817ae60f","volume":"51","author":"AP Singh","year":"2008","unstructured":"Singh AP, Singh M, Balakumar P: Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J Cardiovasc Pharmacol. 2008, 51: 596-604. 10.1097\/FJC.0b013e31817ae60f.","journal-title":"J Cardiovasc Pharmacol"},{"key":"268_CR14","doi-asserted-by":"crossref","first-page":"H1239","DOI":"10.1152\/ajpheart.2000.279.3.H1239","volume":"279","author":"S Nosaka","year":"2000","unstructured":"Nosaka S, Murata K, Kobayashi M, Cheng ZB, Maruyama J: Inhibition of baroreflex vagal bradycardia by activation of the rostral ventrolateral medulla in rats. Am J Physiol Heart Circ Physiol. 2000, 279: H1239-H1247.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"Pt 1","key":"268_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1469-7793.2000.t01-1-00157.x","volume":"526","author":"Y Wang","year":"2000","unstructured":"Wang Y, Jones JF, Jeggo RD, de Burgh DM, Jordan D, Ramage AG: Effect of pulmonary C-fibre afferent stimulation on cardiac vagal neurones in the nucleus ambiguus in anaesthetized cats. J Physiol. 2000, 526 (Pt 1): 157-165. 10.1111\/j.1469-7793.2000.t01-1-00157.x.","journal-title":"J Physiol"},{"key":"268_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijdevneu.2010.02.006","volume":"28","author":"ST Koz","year":"2010","unstructured":"Koz ST, Gouwy NT, Demir N, Nedzvetsky VS, Etem E, Baydas G: Effects of maternal hyperhomocysteinemia induced by methionine intake on oxidative stress and apoptosis in pup rat brain. Int J Dev Neurosci. 2010, 28: 325-329. 10.1016\/j.ijdevneu.2010.02.006.","journal-title":"Int J Dev Neurosci"},{"key":"268_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1073\/pnas.0909737107","volume":"107","author":"M Sibrian-Vazquez","year":"2010","unstructured":"Sibrian-Vazquez M, Escobedo JO, Lim S, Samoei GK, Strongin RM: Homocystamides promote free-radical and oxidative damage to proteins. Proc Natl Acad Sci USA. 2010, 107: 551-554. 10.1073\/pnas.0909737107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"268_CR18","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00125-006-0377-2","volume":"49","author":"A Solini","year":"2006","unstructured":"Solini A, Santini E, Nannipieri M, Ferrannini E: High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts. Diabetologia. 2006, 49: 2499-2506. 10.1007\/s00125-006-0377-2.","journal-title":"Diabetologia"},{"key":"268_CR19","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/sj.ijo.0803265","volume":"30","author":"A Solini","year":"2006","unstructured":"Solini A, Santini E, Ferrannini E: Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. Int J Obes (Lond). 2006, 30: 1197-1202. 10.1038\/sj.ijo.0803265.","journal-title":"Int J Obes (Lond)"},{"key":"268_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jcb.20137","volume":"93","author":"S Shastry","year":"2004","unstructured":"Shastry S, Tyagi SC: Homocysteine induces metalloproteinase and shedding of beta-1 integrin in microvessel endothelial cells. J Cell Biochem. 2004, 93: 207-213. 10.1002\/jcb.20137.","journal-title":"J Cell Biochem"},{"key":"268_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7150\/ijbs.4.236","volume":"4","author":"WE Rodriguez","year":"2008","unstructured":"Rodriguez WE, Sen U, Tyagi N, Kumar M, Carneal G, Aggrawal D, et al: PPAR gamma agonist normalizes glomerular filtration rate, tissue levels of homocysteine, and attenuates endothelial-myocyte uncoupling in alloxan induced diabetic mice. Int J Biol Sci. 2008, 4: 236-244.","journal-title":"Int J Biol Sci"},{"key":"268_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/107424840200700407","volume":"7","author":"SC Tyagi","year":"2002","unstructured":"Tyagi SC, Hoit BD: Metalloproteinase in myocardial adaptation and maladaptation. J Cardiovasc Pharmacol Ther. 2002, 7: 241-246. 10.1177\/107424840200700407.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"268_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jech.55.2.91","volume":"55","author":"UB Fallon","year":"2001","unstructured":"Fallon UB, Elwood P, Ben-Shlomo Y, Ubbink JB, Greenwood R, Smith GD: Homocysteine and ischaemic stroke in men: the Caerphilly study. J Epidemiol Community Health. 2001, 55: 91-96. 10.1136\/jech.55.2.91.","journal-title":"J Epidemiol Community Health"},{"key":"268_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0021-9150(02)00386-6","volume":"167","author":"VA Fonseca","year":"2003","unstructured":"Fonseca VA, Fink LM, Kern PA: Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects. Atherosclerosis. 2003, 167: 105-109. 10.1016\/S0021-9150(02)00386-6.","journal-title":"Atherosclerosis"},{"key":"268_CR25","doi-asserted-by":"publisher","first-page":"H2096","DOI":"10.1152\/ajpheart.00452.2009","volume":"297","author":"R Basu","year":"2009","unstructured":"Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, et al: Type 1 diabetic cardiomyopathy in the Akita (Ins2WT\/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol. 2009, 297: H2096-H2108. 10.1152\/ajpheart.00452.2009.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"34","key":"268_CR26","doi-asserted-by":"publisher","first-page":"26358","DOI":"10.1074\/jbc.M110.147439","volume":"20;285","author":"I Ishii","year":"2010","unstructured":"Ishii I, Akahoshi N, Yamada H, Nakano S, Izumi T, Suematsu M: Cystathionine {gamma}-lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. J Biol Chem. 2010, 20;285 (34): 26358-68. 10.1074\/jbc.M110.147439. Epub 2010 Jun 21","journal-title":"J Biol Chem"},{"key":"268_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1159\/000296717","volume":"31","author":"U Sen","year":"2010","unstructured":"Sen U, Munjal C, Qipshidze N, Abe O, Gargoum R, Tyagi SC: Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol. 2010, 31: 442-455. 10.1159\/000296717.","journal-title":"Am J Nephrol"},{"key":"268_CR28","first-page":"441","volume":"46","author":"N Tyagi","year":"2009","unstructured":"Tyagi N, Mishra PK, Tyagi SC: Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure. Indian J Biochem Biophys. 2009, 46: 441-446.","journal-title":"Indian J Biochem Biophys"},{"key":"268_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.neuint.2009.11.002","volume":"56","author":"N Tyagi","year":"2010","unstructured":"Tyagi N, Givvimani S, Qipshidze N, Kundu S, Kapoor S, Vacek JC, et al: Hydrogen sulfide mitigates matrix metalloproteinase-9 activity and neurovascular permeability in hyperhomocysteinemic mice. Neurochem Int. 2010, 56: 301-307. 10.1016\/j.neuint.2009.11.002.","journal-title":"Neurochem Int"},{"key":"268_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1475-2840-2-4","volume":"2","author":"A Tenenbaum","year":"2003","unstructured":"Tenenbaum A, Fisman EZ, Motro M: Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol. 2003, 2: 4-10.1186\/1475-2840-2-4.","journal-title":"Cardiovasc Diabetol"},{"key":"268_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11883-005-0077-2","volume":"7","author":"CD Folmes","year":"2005","unstructured":"Folmes CD, Clanachan AS, Lopaschuk GD: Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep. 2005, 7: 63-70. 10.1007\/s11883-005-0077-2.","journal-title":"Curr Atheroscler Rep"},{"key":"268_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/25931","volume":"395","author":"RT Nolte","year":"1998","unstructured":"Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998, 395: 137-143. 10.1038\/25931.","journal-title":"Nature"},{"key":"268_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1046\/j.1440-1681.1999.03082.x","volume":"26","author":"H Itoh","year":"1999","unstructured":"Itoh H, Doi K, Tanaka T, Fukunaga Y, Hosoda K, Inoue G, et al: Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Clin Exp Pharmacol Physiol. 1999, 26: 558-560. 10.1046\/j.1440-1681.1999.03082.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"268_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1210\/rp.56.1.265","volume":"56","author":"HE Lebovitz","year":"2001","unstructured":"Lebovitz HE, Banerji MA: Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001, 56: 265-294. 10.1210\/rp.56.1.265.","journal-title":"Recent Prog Horm Res"},{"key":"268_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0002-9440(10)65540-X","volume":"153","author":"N Marx","year":"1998","unstructured":"Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998, 153: 17-23.","journal-title":"Am J Pathol"},{"key":"268_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0021-9150(00)00584-0","volume":"155","author":"R Bissonnette","year":"2001","unstructured":"Bissonnette R, Treacy E, Rozen R, Boucher B, Cohn JS, Genest J: Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis. 2001, 155: 455-462. 10.1016\/S0021-9150(00)00584-0.","journal-title":"Atherosclerosis"},{"key":"268_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/0002-9343(87)90868-0","volume":"83","author":"GF Blane","year":"1987","unstructured":"Blane GF: Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med. 1987, 83: 26-36. 10.1016\/0002-9343(87)90868-0.","journal-title":"Am J Med"},{"key":"268_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(99)02153-4","volume":"354","author":"J Dierkes","year":"1999","unstructured":"Dierkes J, Westphal S, Luley C: Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999, 354: 219-220. 10.1016\/S0140-6736(99)02153-4.","journal-title":"Lancet"},{"key":"268_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1046\/j.1365-2362.1999.00419.x","volume":"29","author":"IR Brude","year":"1999","unstructured":"Brude IR, Finstad HS, Seljeflot I, Drevon CA, Solvoll K, Sandstad B, et al: Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest. 1999, 29: 100-108. 10.1046\/j.1365-2362.1999.00419.x.","journal-title":"Eur J Clin Invest"},{"key":"268_CR40","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1172\/JCI9056","volume":"105","author":"PM Barger","year":"2000","unstructured":"Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP: Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest. 2000, 105: 1723-1730. 10.1172\/JCI9056.","journal-title":"J Clin Invest"},{"key":"268_CR41","doi-asserted-by":"publisher","first-page":"C1073","DOI":"10.1152\/ajpcell.00152.2002","volume":"283","author":"MJ Hunt","year":"2002","unstructured":"Hunt MJ, Tyagi SC: Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. Am J Physiol Cell Physiol. 2002, 283: C1073-C1079.","journal-title":"Am J Physiol Cell Physiol"},{"key":"268_CR42","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/hc4001.097186","volume":"104","author":"K Yamamoto","year":"2001","unstructured":"Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K: Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001, 104: 1670-1675. 10.1161\/hc4001.097186.","journal-title":"Circulation"},{"key":"268_CR43","doi-asserted-by":"publisher","first-page":"H1047","DOI":"10.1152\/ajpheart.01071.2004","volume":"289","author":"DK Jagadeesha","year":"2005","unstructured":"Jagadeesha DK, Lindley TE, Deleon J, Sharma RV, Miller F, Bhalla RC: Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats. Am J Physiol Heart Circ Physiol. 2005, 289: H1047-H1053. 10.1152\/ajpheart.01071.2004.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"268_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.phrs.2005.11.002","volume":"53","author":"B Viswanad","year":"2006","unstructured":"Viswanad B, Srinivasan K, Kaul CL, Ramarao P: Effect of tempol on altered angiotensin II and acetylcholine-mediated vascular responses in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res. 2006, 53: 209-215. 10.1016\/j.phrs.2005.11.002.","journal-title":"Pharmacol Res"},{"key":"268_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1475-2840-4-5","volume":"4","author":"JS Johansen","year":"2005","unstructured":"Johansen JS, Harris AK, Rychly DJ, Ergul A: Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005, 4: 5-10.1186\/1475-2840-4-5.","journal-title":"Cardiovasc Diabetol"},{"key":"268_CR46","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1073\/pnas.92.5.1585","volume":"92","author":"M Watanabe","year":"1995","unstructured":"Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, et al: Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA. 1995, 92: 1585-1589. 10.1073\/pnas.92.5.1585.","journal-title":"Proc Natl Acad Sci USA"},{"key":"268_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1124\/jpet.104.080598","volume":"313","author":"A Sivarajah","year":"2005","unstructured":"Sivarajah A, McDonald MC, Thiemermann C: The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther. 2005, 313: 896-901. 10.1124\/jpet.104.080598.","journal-title":"J Pharmacol Exp Ther"},{"key":"268_CR48","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1161\/01.CIR.101.15.1773","volume":"101","author":"M Evans","year":"2000","unstructured":"Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, et al: Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000, 101: 1773-1779.","journal-title":"Circulation"},{"key":"268_CR49","doi-asserted-by":"publisher","first-page":"256251","DOI":"10.1155\/2008\/256251","volume":"2008","author":"R Scatena","year":"2008","unstructured":"Scatena R, Bottoni P, Giardina B: Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?. PPAR Res. 2008, 2008: 256251.","journal-title":"PPAR Res"},{"key":"268_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11030-006-9038-0","volume":"10","author":"L Guo","year":"2006","unstructured":"Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, et al: Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers. 2006, 10: 349-360. 10.1007\/s11030-006-9038-0.","journal-title":"Mol Divers"},{"key":"268_CR51","doi-asserted-by":"publisher","first-page":"C1779","DOI":"10.1152\/ajpcell.00207.2007","volume":"293","author":"U Sen","year":"2007","unstructured":"Sen U, Tyagi N, Kumar M, Moshal KS, Rodriguez WE, Tyagi SC: Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells. Am J Physiol Cell Physiol. 2007, 293: C1779-C1787. 10.1152\/ajpcell.00207.2007.","journal-title":"Am J Physiol Cell Physiol"},{"key":"268_CR52","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1139\/y99-102","volume":"77","author":"SC Tyagi","year":"1999","unstructured":"Tyagi SC, Smiley LM, Mujumdar VS: Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol. 1999, 77: 950-957. 10.1139\/cjpp-77-12-950.","journal-title":"Can J Physiol Pharmacol"},{"key":"268_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12013-009-9063-6","volume":"55","author":"PK Mishra","year":"2009","unstructured":"Mishra PK, Tyagi N, Kundu S, Tyagi SC: MicroRNAs are involved in homocysteine-induced cardiac remodeling. Cell Biochem Biophys. 2009, 55: 153-162. 10.1007\/s12013-009-9063-6.","journal-title":"Cell Biochem Biophys"},{"key":"268_CR54","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1073\/pnas.0910533107","volume":"107","author":"I Garin","year":"2010","unstructured":"Garin I, Edghill EL, Akerman I, Rubio-Cabezas O, Rica I, Locke JM, et al: Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc Natl Acad Sci USA. 2010, 107: 3105-3110. 10.1073\/pnas.0910533107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"268_CR55","doi-asserted-by":"publisher","first-page":"E1687","DOI":"10.1152\/ajpendo.00256.2007","volume":"293","author":"EG Hong","year":"2007","unstructured":"Hong EG, Jung DY, Ko HJ, Zhang Z, Ma Z, Jun JY, et al: Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab. 2007, 293: E1687-E1696. 10.1152\/ajpendo.00256.2007.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"268_CR56","volume-title":"Physiol Res","author":"M Adamcova","year":"2010","unstructured":"Adamcova M, Potacova A, Popelova O, Sterba M, Mazurova Y, Aupperle H, et al: Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res. 2010."},{"key":"268_CR57","doi-asserted-by":"publisher","first-page":"C679","DOI":"10.1152\/ajpcell.00351.2009","volume":"298","author":"AE Awad","year":"2010","unstructured":"Awad AE, Kandalam V, Chakrabarti S, Wang X, Penninger JM, Davidge ST, et al: Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol. 2010, 298: C679-C692. 10.1152\/ajpcell.00351.2009.","journal-title":"Am J Physiol Cell Physiol"},{"key":"268_CR58","doi-asserted-by":"publisher","first-page":"H451","DOI":"10.1152\/ajpheart.00682.2009","volume":"298","author":"PK Mishra","year":"2010","unstructured":"Mishra PK, Tyagi N, Sen U, Givvimani S, Tyagi SC: H2 S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol. 2010, 298: H451-H456. 10.1152\/ajpheart.00682.2009.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"268_CR59","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1292\/jvms.09-0582","volume":"72","author":"M Okada","year":"2010","unstructured":"Okada M, Yamawaki H, Hara Y: Angiotensin II enhances interleukin-1 beta-induced MMP-9 secretion in adult rat cardiac fibroblasts. J Vet Med Sci. 2010, 72: 735-739. 10.1292\/jvms.09-0582.","journal-title":"J Vet Med Sci"},{"key":"268_CR60","first-page":"143","volume":"102","author":"A Maheshwari","year":"2004","unstructured":"Maheshwari A, Singh AK, Sinha DK, Tripathi K, Prakash J: Spectrum of renal disease in malaria. J Indian Med Assoc. 2004, 102: 143-146, 148","journal-title":"J Indian Med Assoc"},{"key":"268_CR61","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1161\/HYPERTENSIONAHA.109.149112","volume":"55","author":"A Gonzalez","year":"2010","unstructured":"Gonzalez A, Lopez B, Querejeta R, Zubillaga E, Echeverria T, Diez J: Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension. 2010, 55: 1418-1424. 10.1161\/HYPERTENSIONAHA.109.149112.","journal-title":"Hypertension"},{"key":"268_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11357-008-9077-9","volume":"31","author":"F Gramley","year":"2009","unstructured":"Gramley F, Lorenzen J, Knackstedt C, Rana OR, Saygili E, Frechen D, et al: Age-related atrial fibrosis. Age (Dordr). 2009, 31: 27-38. 10.1007\/s11357-008-9077-9.","journal-title":"Age (Dordr)"},{"key":"268_CR63","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1161\/ATVBAHA.108.170548","volume":"28","author":"JL Johnson","year":"2008","unstructured":"Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, Newby AC: Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol. 2008, 28: 1647-1653. 10.1161\/ATVBAHA.108.170548.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"268_CR64","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","volume":"356","author":"M Boaz","year":"2000","unstructured":"Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000, 356: 1213-1218. 10.1016\/S0140-6736(00)02783-5.","journal-title":"Lancet"},{"key":"268_CR65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000107513","volume":"20","author":"D Bell","year":"2007","unstructured":"Bell D, Zhao Y, McCoy FP, Devine AB, McDermott BJ: Differential effects of an anti-oxidant intervention on cardiomyocyte expression of adrenomedullin and intermedin and their receptor components in chronic nitric oxide deficiency. Cell Physiol Biochem. 2007, 20: 269-282. 10.1159\/000107513.","journal-title":"Cell Physiol Biochem"},{"key":"268_CR66","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0891-5849(97)00079-8","volume":"23","author":"SM Hahn","year":"1997","unstructured":"Hahn SM, Mitchell JB, Shacter E: Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic Biol Med. 1997, 23: 879-884. 10.1016\/S0891-5849(97)00079-8.","journal-title":"Free Radic Biol Med"},{"key":"268_CR67","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1474-9726.2010.00557.x","volume":"9","author":"C Rippe","year":"2010","unstructured":"Rippe C, Lesniewski L, Connell M, LaRocca T, Donato A, Seals D: Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell. 2010, 9: 304-312. 10.1111\/j.1474-9726.2010.00557.x.","journal-title":"Aging Cell"},{"key":"268_CR68","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1097\/00004872-200308000-00015","volume":"21","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Jang R, Mori TA, Croft KD, Schyvens CG, McKenzie KU, et al: The anti-oxidant Tempol reverses and partially prevents adrenocorticotrophic hormone-induced hypertension in the rat. J Hypertens. 2003, 21: 1513-1518. 10.1097\/00004872-200308000-00015.","journal-title":"J Hypertens"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-9-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:40:04Z","timestamp":1740505204000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/1475-2840-9-49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,9]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1186\/1475-2840-9-49","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,9]]},"assertion":[{"value":"9 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"49"}}